Irene Rodriguez-Sanchez

ORCID: 0000-0001-5714-680X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cytomegalovirus and herpesvirus research
  • Cancer Genomics and Diagnostics
  • Sarcoma Diagnosis and Treatment
  • Glioma Diagnosis and Treatment
  • Hematopoietic Stem Cell Transplantation
  • Immune Cell Function and Interaction
  • Polyomavirus and related diseases
  • Genetic factors in colorectal cancer
  • CAR-T cell therapy research
  • Herpesvirus Infections and Treatments
  • Viral Infections and Immunology Research
  • Genomics and Rare Diseases
  • Acute Myeloid Leukemia Research
  • Adolescent Sexual and Reproductive Health
  • Urinary Tract Infections Management
  • Acute Lymphoblastic Leukemia research
  • Climate Change and Health Impacts
  • Neuroblastoma Research and Treatments
  • Systemic Sclerosis and Related Diseases
  • Single-cell and spatial transcriptomics
  • Eosinophilic Disorders and Syndromes
  • Renal and related cancers
  • Retinoids in leukemia and cellular processes
  • Pancreatic and Hepatic Oncology Research
  • Pneumocystis jirovecii pneumonia detection and treatment

Memorial Sloan Kettering Cancer Center
2016-2023

Kettering University
2021

Abstract Background Safe sampling of central nervous system tumor tissue for diagnostic purposes may be difficult if not impossible, especially in pediatric patients, and an unmet need exists to develop less invasive tests. Methods We report our clinical experience with minimally molecular diagnostics using a clinically validated assay sequencing cerebrospinal fluid (CSF) cell-free DNA (cfDNA). All CSF samples were collected as part care, results reported both clinicians patients/families....

10.1093/neuonc/noac035 article EN Neuro-Oncology 2022-02-08

Abstract The utility of cancer whole genome and transcriptome sequencing (cWGTS) in oncology is increasingly recognized. However, implementation cWGTS challenged by the need to deliver results within clinically relevant timeframes, concerns about assay sensitivity, reporting prioritization findings. In a prospective research study we develop workflow that reports comprehensive 9 days. Comparison diagnostic panel assays demonstrates potential capture all reported mutations with comparable...

10.1038/s41467-022-30233-7 article EN cc-by Nature Communications 2022-05-18

Abstract Adoptive cell therapy using cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CMV-CTLs) has demonstrated efficacy posttransplant. Despite the predicted limited engraftment of CMV-CTLs derived from third-party donors, partially matched donor–derived have similar response rates to those primary hematopoietic transplantation donors. Little is known about mechanisms through which adoptive cellular therapies mediate durable responses. We performed a retrospective analysis patients...

10.1182/bloodadvances.2020002735 article EN cc-by-nc-nd Blood Advances 2021-01-22

Abstract Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic relapse site. Subclonal...

10.1158/0008-5472.can-23-0385 article EN cc-by-nc-nd Cancer Research 2023-10-09

Abstract Myeloid/lymphoid neoplasm with eosinophilia (MLN-Eo) is a World Health Organization (WHO) established category of hematologic malignancies primarily arising in adults. We discuss an 8-month-old infant who presented clinical features similar to those juvenile myelomonocytic leukemia (JMML) but was diagnosed MLN-Eo driven by ETV6-FLT3 fusion. Results patient-derived ex vivo studies demonstrated increased sensitivity type I FLT3 inhibitors as compared II inhibitors. Treatment the...

10.1182/bloodadvances.2020003699 article EN cc-by-nc-nd Blood Advances 2021-04-01

PURPOSE The tyrosine kinase receptor anaplastic lymphoma (ALK) can be abnormally activated in neuroblastoma, and somatic ALK mutations occur 6%-10% of patients. differential clinical impact these has not been clearly elucidated. METHODS Data on patients with neuroblastoma harboring were retrospectively analyzed. sequencing was performed by whole-genome sequencing, hybrid-based capture targeted exomes, or hotspot mutation profiling. site characteristics, response to treatment, survival In a...

10.1200/po.20.00181 article EN JCO Precision Oncology 2021-03-19

FIP1L1-RARA-a ssociated neoplasm is a very rare and aggressive disease, with only 3 previously reported cases in the literature. Here, we describe 9-month-old boy who presented FIP1L1-RARA fusion-associated myelodysplastic/myeloproliferative neoplasm-like overlap syndrome, similarities distinct features to both acute promyelocytic leukemia juvenile myelomonocytic leukemia. Using combined approach of chemotherapy, differentiating agents, allogeneic hematopoietic stem cell transplant...

10.1182/bloodadvances.2021004966 article EN cc-by-nc-nd Blood Advances 2021-09-22

Multiple large-scale tumor genomic profiling efforts have been undertaken in osteosarcoma, however, little is known about the spatial and temporal intratumor heterogeneity how it may drive treatment resistance. We performed whole-genome sequencing of 37 samples from eight patients with relapsed or refractory osteosarcoma. Each patient had at least one sample a primary site metastatic relapse site. identified subclonal copy number alterations all but patient. observed that five patients,...

10.1101/2023.01.05.522765 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2023-01-06

Abstract Purpose Pediatric central nervous system tumors remain a leading cause of cancer-related death in children and adolescents. Safe sampling tumor tissue for diagnostic purposes may be challenging. Subclinical detection disease prior to clinical or imaging progression provide opportunity earlier intervention ultimately improve overall survival. Additionally, our understanding molecular evolution response therapy remains limited, given the rarity serial tissue. Methods We report...

10.1093/neuonc/noab090.207 article EN cc-by-nc Neuro-Oncology 2021-06-01

Background Despite significant advances in viral detection and treatment, reactivation of cytomegalovirus (CMV) remains a major complication following allogeneic hematopoietic cell transplant (allo-HCT). Methods to decrease the risk CMV long-term sequelae disease include controlling for known factors administering appropriate antiviral treatments. Although they are shown be effective, these treatments carry considerable adverse effects that may limit their use. The optimal timing initiate...

10.1016/j.bbmt.2019.12.382 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2020-01-23

Abstract Pediatric CNS tumors remain the leading cause of cancer-related death in children and adolescents. Safe sampling tumor tissue for diagnostic purposes may be difficult if not impossible. Detection minimal residual or recurrent disease prior to definitive clinical radiographic progression allow earlier initiation novel therapies ultimately improve overall survival. Given rarity serial tissue, our understanding molecular evolution response therapy remains limited. Recent technological...

10.1093/neuonc/noaa215.053 article EN Neuro-Oncology 2020-11-01

Urinary tract infection (UTI) due to Escherichia Coli is considered the most commonly acquired bacterial in women. Currently used treatments for UTI prevention have conflicting evidence regarding efficacy. There minimum information use of Vitamin D and its effect on modulating innate adaptive immune system, favoring production endogenous antimicrobial peptides such as Cathelicidin. It has been suggested that inducing Cathelicidin bladder a potential complement preventing UTI. This clinical...

10.21801/issn.2378-1890.2016.4 article EN 2016-03-15

Urinary tract infection (UTI) due to Escherichia Coli is considered the most commonly acquired bacterial in women. Currently used treatments for UTI prevention have conflicting evidence regarding efficacy. There minimum information use of Vitamin D and its effect on modulating innate adaptive immune system, favoring production endogenous antimicrobial peptides such as Cathelicidin. It has been suggested that inducing Cathelicidin bladder a potential complement preventing UTI. This clinical...

10.21801/ppcrj.2016.21.4 article EN Principles and Practice of Clinical Research Journal 2016-03-15

<div>Abstract<p>Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic...

10.1158/0008-5472.c.6931223.v1 preprint EN 2023-11-15

<div>Abstract<p>Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic...

10.1158/0008-5472.c.6931223 preprint EN 2023-11-15

BackgroundAdoptive cell therapy using CMV-specific cytotoxic T-cells (CMV CTLs) has demonstrated efficacy in treating CMV the post HCT setting. However, little is known about mechanism by which adoptively transferred CTLs exert durable responses. Therefore, we studied relationship between response and recipient factors.MethodsWe retrospectively reviewed pediatric adult patients (pts) who received primary or 3rd party donor for treatment of viremia/disease after 9/2009 1/2018. Outcomes...

10.1016/j.bbmt.2019.12.363 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2020-01-23
Coming Soon ...